nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—thymus cancer	0.448	1	CtDrD
Sorafenib—MUSK—thymus cancer	0.364	0.829	CbGaD
Sorafenib—KIT—thymus cancer	0.0749	0.171	CbGaD
Sorafenib—Abdominal tenderness—Octreotide—thymus cancer	0.00321	0.0834	CcSEcCtD
Sorafenib—Ischaemia—Octreotide—thymus cancer	0.00222	0.0577	CcSEcCtD
Sorafenib—Regorafenib—KIT—thymus cancer	0.00218	1	CrCbGaD
Sorafenib—RET—parathyroid gland—thymus cancer	0.00156	0.0326	CbGeAlD
Sorafenib—Cholecystitis—Octreotide—thymus cancer	0.00141	0.0367	CcSEcCtD
Sorafenib—Gastrointestinal symptom NOS—Octreotide—thymus cancer	0.00138	0.0358	CcSEcCtD
Sorafenib—Haematoma—Octreotide—thymus cancer	0.00129	0.0335	CcSEcCtD
Sorafenib—Hypothyroidism—Octreotide—thymus cancer	0.00126	0.0328	CcSEcCtD
Sorafenib—Oropharyngeal discomfort—Octreotide—thymus cancer	0.00111	0.029	CcSEcCtD
Sorafenib—Endocrine disorder—Octreotide—thymus cancer	0.000978	0.0254	CcSEcCtD
Sorafenib—Neoplasm malignant—Octreotide—thymus cancer	0.00095	0.0247	CcSEcCtD
Sorafenib—Drug interaction—Octreotide—thymus cancer	0.000874	0.0227	CcSEcCtD
Sorafenib—Influenza like illness—Octreotide—thymus cancer	0.000788	0.0205	CcSEcCtD
Sorafenib—Neuropathy—Octreotide—thymus cancer	0.000761	0.0198	CcSEcCtD
Sorafenib—Mouth ulceration—Octreotide—thymus cancer	0.000733	0.019	CcSEcCtD
Sorafenib—Gynaecomastia—Octreotide—thymus cancer	0.000726	0.0188	CcSEcCtD
Sorafenib—MAPK15—thyroid gland—thymus cancer	0.000668	0.014	CbGeAlD
Sorafenib—Cardiac failure congestive—Octreotide—thymus cancer	0.000649	0.0169	CcSEcCtD
Sorafenib—CDK7—hematopoietic system—thymus cancer	0.00061	0.0127	CbGeAlD
Sorafenib—Pain in extremity—Octreotide—thymus cancer	0.000589	0.0153	CcSEcCtD
Sorafenib—Dehydration—Octreotide—thymus cancer	0.000547	0.0142	CcSEcCtD
Sorafenib—Dry skin—Octreotide—thymus cancer	0.00054	0.014	CcSEcCtD
Sorafenib—Abdominal pain upper—Octreotide—thymus cancer	0.000538	0.014	CcSEcCtD
Sorafenib—ZAK—hematopoietic system—thymus cancer	0.000527	0.011	CbGeAlD
Sorafenib—Nasopharyngitis—Octreotide—thymus cancer	0.000526	0.0137	CcSEcCtD
Sorafenib—Gastritis—Octreotide—thymus cancer	0.000521	0.0135	CcSEcCtD
Sorafenib—Pancreatitis—Octreotide—thymus cancer	0.000499	0.013	CcSEcCtD
Sorafenib—Abdominal discomfort—Octreotide—thymus cancer	0.000488	0.0127	CcSEcCtD
Sorafenib—TIE1—hematopoietic system—thymus cancer	0.000482	0.0101	CbGeAlD
Sorafenib—RET—neck—thymus cancer	0.000472	0.00987	CbGeAlD
Sorafenib—Weight decreased—Octreotide—thymus cancer	0.00046	0.012	CcSEcCtD
Sorafenib—Pneumonia—Octreotide—thymus cancer	0.000456	0.0119	CcSEcCtD
Sorafenib—TAOK2—pituitary gland—thymus cancer	0.000449	0.00937	CbGeAlD
Sorafenib—Neuropathy peripheral—Octreotide—thymus cancer	0.000445	0.0115	CcSEcCtD
Sorafenib—Jaundice—Octreotide—thymus cancer	0.000442	0.0115	CcSEcCtD
Sorafenib—TIE1—epithelium—thymus cancer	0.00044	0.0092	CbGeAlD
Sorafenib—FLT3—hematopoietic system—thymus cancer	0.000438	0.00916	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—thymus cancer	0.000429	0.00897	CbGeAlD
Sorafenib—Hepatobiliary disease—Octreotide—thymus cancer	0.000429	0.0111	CcSEcCtD
Sorafenib—Epistaxis—Octreotide—thymus cancer	0.000428	0.0111	CcSEcCtD
Sorafenib—FLT1—neck—thymus cancer	0.000416	0.00869	CbGeAlD
Sorafenib—RAF1—neck—thymus cancer	0.000414	0.00864	CbGeAlD
Sorafenib—FLT4—hematopoietic system—thymus cancer	0.000398	0.00832	CbGeAlD
Sorafenib—MAPK11—thyroid gland—thymus cancer	0.000396	0.00828	CbGeAlD
Sorafenib—HIPK3—cardiac atrium—thymus cancer	0.000392	0.00818	CbGeAlD
Sorafenib—CDK7—thyroid gland—thymus cancer	0.00039	0.00814	CbGeAlD
Sorafenib—TAOK2—thyroid gland—thymus cancer	0.000387	0.00808	CbGeAlD
Sorafenib—AURKC—thyroid gland—thymus cancer	0.000384	0.00802	CbGeAlD
Sorafenib—HIPK3—pituitary gland—thymus cancer	0.000382	0.00799	CbGeAlD
Sorafenib—Tinnitus—Octreotide—thymus cancer	0.00038	0.00986	CcSEcCtD
Sorafenib—Flushing—Octreotide—thymus cancer	0.000378	0.00982	CcSEcCtD
Sorafenib—Cardiac disorder—Octreotide—thymus cancer	0.000378	0.00982	CcSEcCtD
Sorafenib—ZAK—lymphoid tissue—thymus cancer	0.000371	0.00775	CbGeAlD
Sorafenib—Immune system disorder—Octreotide—thymus cancer	0.000368	0.00955	CcSEcCtD
Sorafenib—TIE1—cardiac atrium—thymus cancer	0.000366	0.00764	CbGeAlD
Sorafenib—FLT4—epithelium—thymus cancer	0.000364	0.0076	CbGeAlD
Sorafenib—Arrhythmia—Octreotide—thymus cancer	0.000364	0.00945	CcSEcCtD
Sorafenib—MKNK2—hematopoietic system—thymus cancer	0.00036	0.00753	CbGeAlD
Sorafenib—Alopecia—Octreotide—thymus cancer	0.00036	0.00935	CcSEcCtD
Sorafenib—Mental disorder—Octreotide—thymus cancer	0.000357	0.00927	CcSEcCtD
Sorafenib—MKNK1—hematopoietic system—thymus cancer	0.000356	0.00744	CbGeAlD
Sorafenib—Erythema—Octreotide—thymus cancer	0.000354	0.00921	CcSEcCtD
Sorafenib—Malnutrition—Octreotide—thymus cancer	0.000354	0.00921	CcSEcCtD
Sorafenib—CDK7—lung—thymus cancer	0.000354	0.0074	CbGeAlD
Sorafenib—KDR—neck—thymus cancer	0.000352	0.00735	CbGeAlD
Sorafenib—RET—hematopoietic system—thymus cancer	0.000352	0.00734	CbGeAlD
Sorafenib—TAOK2—lung—thymus cancer	0.000351	0.00734	CbGeAlD
Sorafenib—BRAF—pituitary gland—thymus cancer	0.000343	0.00716	CbGeAlD
Sorafenib—Muscle spasms—Octreotide—thymus cancer	0.000341	0.00885	CcSEcCtD
Sorafenib—ZAK—thyroid gland—thymus cancer	0.000337	0.00704	CbGeAlD
Sorafenib—HIPK3—bone marrow—thymus cancer	0.000331	0.00691	CbGeAlD
Sorafenib—HIPK3—thyroid gland—thymus cancer	0.00033	0.00689	CbGeAlD
Sorafenib—MKNK2—epithelium—thymus cancer	0.000329	0.00688	CbGeAlD
Sorafenib—Anaemia—Octreotide—thymus cancer	0.000328	0.00851	CcSEcCtD
Sorafenib—EPHX2—pituitary gland—thymus cancer	0.000328	0.00684	CbGeAlD
Sorafenib—RALBP1—hematopoietic system—thymus cancer	0.000326	0.0068	CbGeAlD
Sorafenib—RET—epithelium—thymus cancer	0.000321	0.00671	CbGeAlD
Sorafenib—Syncope—Octreotide—thymus cancer	0.000318	0.00826	CcSEcCtD
Sorafenib—KIT—neck—thymus cancer	0.000312	0.00651	CbGeAlD
Sorafenib—Loss of consciousness—Octreotide—thymus cancer	0.000312	0.00809	CcSEcCtD
Sorafenib—FLT1—hematopoietic system—thymus cancer	0.00031	0.00647	CbGeAlD
Sorafenib—Cough—Octreotide—thymus cancer	0.000309	0.00803	CcSEcCtD
Sorafenib—FLT3—lymphoid tissue—thymus cancer	0.000309	0.00645	CbGeAlD
Sorafenib—TIE1—thyroid gland—thymus cancer	0.000308	0.00644	CbGeAlD
Sorafenib—RAF1—hematopoietic system—thymus cancer	0.000308	0.00643	CbGeAlD
Sorafenib—Hypertension—Octreotide—thymus cancer	0.000306	0.00795	CcSEcCtD
Sorafenib—ZAK—lung—thymus cancer	0.000306	0.00639	CbGeAlD
Sorafenib—PDGFRB—neck—thymus cancer	0.000304	0.00636	CbGeAlD
Sorafenib—Myalgia—Octreotide—thymus cancer	0.000302	0.00784	CcSEcCtD
Sorafenib—Arthralgia—Octreotide—thymus cancer	0.000302	0.00784	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.0003	0.00778	CcSEcCtD
Sorafenib—HIPK3—lung—thymus cancer	0.000299	0.00626	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—thymus cancer	0.000298	0.00623	CbGeAlD
Sorafenib—BRAF—bone marrow—thymus cancer	0.000296	0.00619	CbGeAlD
Sorafenib—BRAF—thyroid gland—thymus cancer	0.000295	0.00617	CbGeAlD
Sorafenib—Dry mouth—Octreotide—thymus cancer	0.000295	0.00767	CcSEcCtD
Sorafenib—MAP3K19—lung—thymus cancer	0.000293	0.00613	CbGeAlD
Sorafenib—STK10—hematopoietic system—thymus cancer	0.000293	0.00612	CbGeAlD
Sorafenib—FGFR1—pituitary gland—thymus cancer	0.000291	0.00609	CbGeAlD
Sorafenib—PDGFRA—hematopoietic system—thymus cancer	0.00029	0.00606	CbGeAlD
Sorafenib—Anaphylactic shock—Octreotide—thymus cancer	0.000289	0.00751	CcSEcCtD
Sorafenib—Infection—Octreotide—thymus cancer	0.000287	0.00747	CcSEcCtD
Sorafenib—Shock—Octreotide—thymus cancer	0.000285	0.00739	CcSEcCtD
Sorafenib—Nervous system disorder—Octreotide—thymus cancer	0.000284	0.00737	CcSEcCtD
Sorafenib—Thrombocytopenia—Octreotide—thymus cancer	0.000283	0.00736	CcSEcCtD
Sorafenib—FLT1—epithelium—thymus cancer	0.000283	0.00591	CbGeAlD
Sorafenib—MAP3K7—cardiac atrium—thymus cancer	0.000282	0.0059	CbGeAlD
Sorafenib—EPHX2—thyroid gland—thymus cancer	0.000282	0.0059	CbGeAlD
Sorafenib—RAF1—epithelium—thymus cancer	0.000281	0.00588	CbGeAlD
Sorafenib—FLT3—bone marrow—thymus cancer	0.000281	0.00587	CbGeAlD
Sorafenib—Skin disorder—Octreotide—thymus cancer	0.000281	0.0073	CcSEcCtD
Sorafenib—FLT4—lymphoid tissue—thymus cancer	0.00028	0.00586	CbGeAlD
Sorafenib—TIE1—lung—thymus cancer	0.00028	0.00585	CbGeAlD
Sorafenib—UGT1A1—hematopoietic system—thymus cancer	0.000277	0.00578	CbGeAlD
Sorafenib—MAP3K7—pituitary gland—thymus cancer	0.000276	0.00576	CbGeAlD
Sorafenib—Anorexia—Octreotide—thymus cancer	0.000276	0.00716	CcSEcCtD
Sorafenib—MKNK2—cardiac atrium—thymus cancer	0.000274	0.00572	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—thymus cancer	0.00027	0.00565	CbGeAlD
Sorafenib—BRAF—lung—thymus cancer	0.000268	0.00561	CbGeAlD
Sorafenib—MKNK2—pituitary gland—thymus cancer	0.000267	0.00559	CbGeAlD
Sorafenib—MKNK1—pituitary gland—thymus cancer	0.000264	0.00552	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000264	0.00685	CcSEcCtD
Sorafenib—KDR—hematopoietic system—thymus cancer	0.000262	0.00547	CbGeAlD
Sorafenib—RET—pituitary gland—thymus cancer	0.000261	0.00545	CbGeAlD
Sorafenib—Dyspnoea—Octreotide—thymus cancer	0.000258	0.0067	CcSEcCtD
Sorafenib—EPHX2—lung—thymus cancer	0.000256	0.00536	CbGeAlD
Sorafenib—CSF1R—hematopoietic system—thymus cancer	0.000255	0.00534	CbGeAlD
Sorafenib—FLT4—bone marrow—thymus cancer	0.000255	0.00533	CbGeAlD
Sorafenib—Dyspepsia—Octreotide—thymus cancer	0.000255	0.00661	CcSEcCtD
Sorafenib—FLT3—lung—thymus cancer	0.000255	0.00532	CbGeAlD
Sorafenib—FLT4—thyroid gland—thymus cancer	0.000255	0.00532	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—thymus cancer	0.000254	0.0053	CbGeAlD
Sorafenib—Decreased appetite—Octreotide—thymus cancer	0.000251	0.00653	CcSEcCtD
Sorafenib—FGFR1—thyroid gland—thymus cancer	0.000251	0.00525	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—thymus cancer	0.000251	0.00523	CbGeAlD
Sorafenib—Gastrointestinal disorder—Octreotide—thymus cancer	0.00025	0.00649	CcSEcCtD
Sorafenib—Fatigue—Octreotide—thymus cancer	0.000249	0.00648	CcSEcCtD
Sorafenib—RET—lymphoid tissue—thymus cancer	0.000247	0.00517	CbGeAlD
Sorafenib—Constipation—Octreotide—thymus cancer	0.000247	0.00643	CcSEcCtD
Sorafenib—Pain—Octreotide—thymus cancer	0.000247	0.00643	CcSEcCtD
Sorafenib—RALBP1—cardiac atrium—thymus cancer	0.000247	0.00516	CbGeAlD
Sorafenib—MAPK11—lymph node—thymus cancer	0.000246	0.00514	CbGeAlD
Sorafenib—CDK7—lymph node—thymus cancer	0.000242	0.00506	CbGeAlD
Sorafenib—RALBP1—pituitary gland—thymus cancer	0.000241	0.00504	CbGeAlD
Sorafenib—TAOK2—lymph node—thymus cancer	0.00024	0.00502	CbGeAlD
Sorafenib—KDR—epithelium—thymus cancer	0.000239	0.005	CbGeAlD
Sorafenib—MAP3K7—bone marrow—thymus cancer	0.000238	0.00498	CbGeAlD
Sorafenib—AURKC—lymph node—thymus cancer	0.000238	0.00498	CbGeAlD
Sorafenib—MAP3K7—thyroid gland—thymus cancer	0.000238	0.00497	CbGeAlD
Sorafenib—Gastrointestinal pain—Octreotide—thymus cancer	0.000237	0.00614	CcSEcCtD
Sorafenib—FLT1—cardiac atrium—thymus cancer	0.000235	0.00491	CbGeAlD
Sorafenib—RAF1—cardiac atrium—thymus cancer	0.000234	0.00488	CbGeAlD
Sorafenib—EPHB6—cardiac atrium—thymus cancer	0.000232	0.00486	CbGeAlD
Sorafenib—KIT—hematopoietic system—thymus cancer	0.000232	0.00485	CbGeAlD
Sorafenib—FLT4—lung—thymus cancer	0.000231	0.00483	CbGeAlD
Sorafenib—MKNK2—bone marrow—thymus cancer	0.000231	0.00483	CbGeAlD
Sorafenib—MKNK2—thyroid gland—thymus cancer	0.00023	0.00482	CbGeAlD
Sorafenib—Urticaria—Octreotide—thymus cancer	0.00023	0.00597	CcSEcCtD
Sorafenib—FLT1—pituitary gland—thymus cancer	0.00023	0.0048	CbGeAlD
Sorafenib—Abdominal pain—Octreotide—thymus cancer	0.000229	0.00594	CcSEcCtD
Sorafenib—Body temperature increased—Octreotide—thymus cancer	0.000229	0.00594	CcSEcCtD
Sorafenib—RAF1—pituitary gland—thymus cancer	0.000228	0.00477	CbGeAlD
Sorafenib—FGFR1—lung—thymus cancer	0.000228	0.00477	CbGeAlD
Sorafenib—MKNK1—bone marrow—thymus cancer	0.000228	0.00477	CbGeAlD
Sorafenib—MKNK1—thyroid gland—thymus cancer	0.000228	0.00475	CbGeAlD
Sorafenib—EPHB6—pituitary gland—thymus cancer	0.000227	0.00474	CbGeAlD
Sorafenib—PDGFRB—hematopoietic system—thymus cancer	0.000227	0.00473	CbGeAlD
Sorafenib—RET—thyroid gland—thymus cancer	0.000225	0.0047	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—thymus cancer	0.000218	0.00455	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—thymus cancer	0.000217	0.00453	CbGeAlD
Sorafenib—MAP3K7—lung—thymus cancer	0.000216	0.00451	CbGeAlD
Sorafenib—Hypersensitivity—Octreotide—thymus cancer	0.000213	0.00554	CcSEcCtD
Sorafenib—KIT—epithelium—thymus cancer	0.000212	0.00443	CbGeAlD
Sorafenib—MKNK2—lung—thymus cancer	0.000209	0.00437	CbGeAlD
Sorafenib—ZAK—lymph node—thymus cancer	0.000209	0.00437	CbGeAlD
Sorafenib—RALBP1—bone marrow—thymus cancer	0.000209	0.00436	CbGeAlD
Sorafenib—RALBP1—thyroid gland—thymus cancer	0.000208	0.00435	CbGeAlD
Sorafenib—Asthenia—Octreotide—thymus cancer	0.000208	0.00539	CcSEcCtD
Sorafenib—PDGFRB—epithelium—thymus cancer	0.000207	0.00433	CbGeAlD
Sorafenib—MKNK1—lung—thymus cancer	0.000207	0.00432	CbGeAlD
Sorafenib—STK10—lymphoid tissue—thymus cancer	0.000206	0.00431	CbGeAlD
Sorafenib—HIPK3—lymph node—thymus cancer	0.000205	0.00428	CbGeAlD
Sorafenib—Pruritus—Octreotide—thymus cancer	0.000205	0.00532	CcSEcCtD
Sorafenib—PDGFRA—lymphoid tissue—thymus cancer	0.000204	0.00427	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—thymus cancer	0.000199	0.00415	CbGeAlD
Sorafenib—KDR—cardiac atrium—thymus cancer	0.000199	0.00415	CbGeAlD
Sorafenib—FLT1—thyroid gland—thymus cancer	0.000198	0.00414	CbGeAlD
Sorafenib—Diarrhoea—Octreotide—thymus cancer	0.000198	0.00514	CcSEcCtD
Sorafenib—RAF1—bone marrow—thymus cancer	0.000197	0.00412	CbGeAlD
Sorafenib—RAF1—thyroid gland—thymus cancer	0.000197	0.00411	CbGeAlD
Sorafenib—EPHB6—thyroid gland—thymus cancer	0.000196	0.00409	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—thymus cancer	0.000194	0.00406	CbGeAlD
Sorafenib—KDR—pituitary gland—thymus cancer	0.000194	0.00406	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—thymus cancer	0.000194	0.00405	CbGeAlD
Sorafenib—TIE1—lymph node—thymus cancer	0.000191	0.004	CbGeAlD
Sorafenib—Dizziness—Octreotide—thymus cancer	0.000191	0.00497	CcSEcCtD
Sorafenib—CSF1R—pituitary gland—thymus cancer	0.000189	0.00396	CbGeAlD
Sorafenib—RALBP1—lung—thymus cancer	0.000189	0.00395	CbGeAlD
Sorafenib—STK10—bone marrow—thymus cancer	0.000188	0.00393	CbGeAlD
Sorafenib—STK10—thyroid gland—thymus cancer	0.000187	0.00392	CbGeAlD
Sorafenib—PDGFRA—thyroid gland—thymus cancer	0.000186	0.00388	CbGeAlD
Sorafenib—KDR—lymphoid tissue—thymus cancer	0.000184	0.00385	CbGeAlD
Sorafenib—Vomiting—Octreotide—thymus cancer	0.000184	0.00478	CcSEcCtD
Sorafenib—BRAF—lymph node—thymus cancer	0.000184	0.00383	CbGeAlD
Sorafenib—Rash—Octreotide—thymus cancer	0.000182	0.00474	CcSEcCtD
Sorafenib—Dermatitis—Octreotide—thymus cancer	0.000182	0.00473	CcSEcCtD
Sorafenib—Headache—Octreotide—thymus cancer	0.000181	0.00471	CcSEcCtD
Sorafenib—ABCC4—hematopoietic system—thymus cancer	0.00018	0.00377	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—thymus cancer	0.00018	0.00376	CbGeAlD
Sorafenib—FLT1—lung—thymus cancer	0.00018	0.00376	CbGeAlD
Sorafenib—RAF1—lung—thymus cancer	0.000179	0.00374	CbGeAlD
Sorafenib—EPHB6—lung—thymus cancer	0.000178	0.00371	CbGeAlD
Sorafenib—EPHX2—lymph node—thymus cancer	0.000175	0.00366	CbGeAlD
Sorafenib—FLT3—lymph node—thymus cancer	0.000174	0.00364	CbGeAlD
Sorafenib—KIT—pituitary gland—thymus cancer	0.000172	0.00359	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—thymus cancer	0.000172	0.00359	CbGeAlD
Sorafenib—Nausea—Octreotide—thymus cancer	0.000172	0.00446	CcSEcCtD
Sorafenib—STK10—lung—thymus cancer	0.00017	0.00356	CbGeAlD
Sorafenib—PDGFRA—lung—thymus cancer	0.000169	0.00352	CbGeAlD
Sorafenib—PDGFRB—pituitary gland—thymus cancer	0.000168	0.00351	CbGeAlD
Sorafenib—KDR—bone marrow—thymus cancer	0.000168	0.00351	CbGeAlD
Sorafenib—KDR—thyroid gland—thymus cancer	0.000167	0.0035	CbGeAlD
Sorafenib—MAP2K5—thyroid gland—thymus cancer	0.000167	0.0035	CbGeAlD
Sorafenib—CSF1R—bone marrow—thymus cancer	0.000164	0.00342	CbGeAlD
Sorafenib—CSF1R—thyroid gland—thymus cancer	0.000163	0.00341	CbGeAlD
Sorafenib—KIT—lymphoid tissue—thymus cancer	0.000163	0.00341	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—thymus cancer	0.000159	0.00333	CbGeAlD
Sorafenib—FLT4—lymph node—thymus cancer	0.000158	0.0033	CbGeAlD
Sorafenib—FGFR1—lymph node—thymus cancer	0.000156	0.00326	CbGeAlD
Sorafenib—KDR—lung—thymus cancer	0.000152	0.00318	CbGeAlD
Sorafenib—MAP2K5—lung—thymus cancer	0.000152	0.00318	CbGeAlD
Sorafenib—CYP2C19—hematopoietic system—thymus cancer	0.00015	0.00313	CbGeAlD
Sorafenib—KIT—bone marrow—thymus cancer	0.000149	0.00311	CbGeAlD
Sorafenib—CSF1R—lung—thymus cancer	0.000148	0.0031	CbGeAlD
Sorafenib—KIT—thyroid gland—thymus cancer	0.000148	0.0031	CbGeAlD
Sorafenib—MAP3K7—lymph node—thymus cancer	0.000148	0.00309	CbGeAlD
Sorafenib—PDGFRB—bone marrow—thymus cancer	0.000145	0.00303	CbGeAlD
Sorafenib—PDGFRB—thyroid gland—thymus cancer	0.000145	0.00303	CbGeAlD
Sorafenib—MKNK2—lymph node—thymus cancer	0.000143	0.00299	CbGeAlD
Sorafenib—MKNK1—lymph node—thymus cancer	0.000141	0.00295	CbGeAlD
Sorafenib—RET—lymph node—thymus cancer	0.00014	0.00292	CbGeAlD
Sorafenib—KIT—lung—thymus cancer	0.000135	0.00281	CbGeAlD
Sorafenib—PDGFRB—lung—thymus cancer	0.000132	0.00275	CbGeAlD
Sorafenib—CYP2C8—hematopoietic system—thymus cancer	0.000131	0.00274	CbGeAlD
Sorafenib—RALBP1—lymph node—thymus cancer	0.000129	0.0027	CbGeAlD
Sorafenib—FLT1—lymph node—thymus cancer	0.000123	0.00257	CbGeAlD
Sorafenib—CYP1A2—hematopoietic system—thymus cancer	0.000123	0.00256	CbGeAlD
Sorafenib—RAF1—lymph node—thymus cancer	0.000122	0.00255	CbGeAlD
Sorafenib—EPHB6—lymph node—thymus cancer	0.000122	0.00254	CbGeAlD
Sorafenib—CYP3A5—hematopoietic system—thymus cancer	0.000118	0.00247	CbGeAlD
Sorafenib—CYP2B6—hematopoietic system—thymus cancer	0.000117	0.00245	CbGeAlD
Sorafenib—STK10—lymph node—thymus cancer	0.000116	0.00243	CbGeAlD
Sorafenib—CYP2C9—hematopoietic system—thymus cancer	0.000116	0.00243	CbGeAlD
Sorafenib—ABCC4—bone marrow—thymus cancer	0.000116	0.00242	CbGeAlD
Sorafenib—ABCC4—thyroid gland—thymus cancer	0.000115	0.00241	CbGeAlD
Sorafenib—PDGFRA—lymph node—thymus cancer	0.000115	0.00241	CbGeAlD
Sorafenib—HTR2B—thyroid gland—thymus cancer	0.000115	0.0024	CbGeAlD
Sorafenib—ABCC4—lung—thymus cancer	0.000105	0.00219	CbGeAlD
Sorafenib—HTR2B—lung—thymus cancer	0.000104	0.00218	CbGeAlD
Sorafenib—KDR—lymph node—thymus cancer	0.000104	0.00217	CbGeAlD
Sorafenib—MAP2K5—lymph node—thymus cancer	0.000104	0.00217	CbGeAlD
Sorafenib—CSF1R—lymph node—thymus cancer	0.000101	0.00212	CbGeAlD
Sorafenib—CYP2C8—pituitary gland—thymus cancer	9.71e-05	0.00203	CbGeAlD
Sorafenib—ABCG2—pituitary gland—thymus cancer	9.44e-05	0.00197	CbGeAlD
Sorafenib—KIT—lymph node—thymus cancer	9.21e-05	0.00192	CbGeAlD
Sorafenib—PDGFRB—lymph node—thymus cancer	9e-05	0.00188	CbGeAlD
Sorafenib—CYP3A4—hematopoietic system—thymus cancer	8.87e-05	0.00185	CbGeAlD
Sorafenib—CYP2D6—hematopoietic system—thymus cancer	8.73e-05	0.00182	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—thymus cancer	8.27e-05	0.00173	CbGeAlD
Sorafenib—ABCG2—bone marrow—thymus cancer	8.16e-05	0.00171	CbGeAlD
Sorafenib—ABCG2—thyroid gland—thymus cancer	8.14e-05	0.0017	CbGeAlD
Sorafenib—CYP1A2—thyroid gland—thymus cancer	7.84e-05	0.00164	CbGeAlD
Sorafenib—ABCG2—lung—thymus cancer	7.39e-05	0.00155	CbGeAlD
Sorafenib—ABCC4—lymph node—thymus cancer	7.16e-05	0.0015	CbGeAlD
Sorafenib—HTR2B—lymph node—thymus cancer	7.13e-05	0.00149	CbGeAlD
Sorafenib—CYP1A2—lung—thymus cancer	7.12e-05	0.00149	CbGeAlD
Sorafenib—ABCC2—lymph node—thymus cancer	6.94e-05	0.00145	CbGeAlD
Sorafenib—CYP3A5—lung—thymus cancer	6.86e-05	0.00143	CbGeAlD
Sorafenib—CYP2B6—lung—thymus cancer	6.82e-05	0.00143	CbGeAlD
Sorafenib—ABCB1—hematopoietic system—thymus cancer	6.28e-05	0.00131	CbGeAlD
Sorafenib—ABCB1—epithelium—thymus cancer	5.74e-05	0.0012	CbGeAlD
Sorafenib—ABCG2—lymph node—thymus cancer	5.06e-05	0.00106	CbGeAlD
Sorafenib—ABCB1—pituitary gland—thymus cancer	4.66e-05	0.000973	CbGeAlD
Sorafenib—ABCB1—lymphoid tissue—thymus cancer	4.42e-05	0.000924	CbGeAlD
Sorafenib—ABCB1—bone marrow—thymus cancer	4.02e-05	0.000841	CbGeAlD
Sorafenib—ABCB1—thyroid gland—thymus cancer	4.01e-05	0.000839	CbGeAlD
Sorafenib—ABCB1—lung—thymus cancer	3.65e-05	0.000762	CbGeAlD
Sorafenib—ABCB1—lymph node—thymus cancer	2.49e-05	0.000521	CbGeAlD
Sorafenib—PDGFRB—Signaling by ERBB2—AKT1—thymus cancer	1.31e-05	0.000535	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 signaling—AKT1—thymus cancer	1.3e-05	0.000532	CbGpPWpGaD
Sorafenib—MKNK1—Disease—CD4—thymus cancer	1.3e-05	0.000529	CbGpPWpGaD
Sorafenib—RAF1—Disease—MAML2—thymus cancer	1.3e-05	0.000529	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling by NGF—AKT1—thymus cancer	1.3e-05	0.000529	CbGpPWpGaD
Sorafenib—RAF1—BDNF signaling pathway—AKT1—thymus cancer	1.29e-05	0.000526	CbGpPWpGaD
Sorafenib—PDGFRA—Focal Adhesion—AKT1—thymus cancer	1.28e-05	0.000525	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	1.28e-05	0.000524	CbGpPWpGaD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.28e-05	0.000524	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.28e-05	0.000523	CbGpPWpGaD
Sorafenib—PDGFRB—MAPK Signaling Pathway—AKT1—thymus cancer	1.28e-05	0.000522	CbGpPWpGaD
Sorafenib—KIT—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.27e-05	0.00052	CbGpPWpGaD
Sorafenib—FGFR1—B Cell Activation—AKT1—thymus cancer	1.26e-05	0.000516	CbGpPWpGaD
Sorafenib—PDGFRA—B Cell Activation—AKT1—thymus cancer	1.26e-05	0.000514	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD8A—thymus cancer	1.26e-05	0.000514	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—AKT1—thymus cancer	1.25e-05	0.000513	CbGpPWpGaD
Sorafenib—RAF1—Downstream signaling of activated FGFR—AKT1—thymus cancer	1.25e-05	0.000512	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—KIT—thymus cancer	1.25e-05	0.00051	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—CD4—thymus cancer	1.24e-05	0.000507	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB4—AKT1—thymus cancer	1.23e-05	0.000504	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by FGFR in disease—AKT1—thymus cancer	1.23e-05	0.000501	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 interactions—AKT1—thymus cancer	1.23e-05	0.000501	CbGpPWpGaD
Sorafenib—PDGFRB—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	1.23e-05	0.000501	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.22e-05	0.000497	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by EGFR—AKT1—thymus cancer	1.21e-05	0.000496	CbGpPWpGaD
Sorafenib—FGFR1—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.21e-05	0.000493	CbGpPWpGaD
Sorafenib—PDGFRA—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.2e-05	0.000492	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by EGFR in Cancer—AKT1—thymus cancer	1.2e-05	0.000492	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by PDGF—AKT1—thymus cancer	1.2e-05	0.00049	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—KIT—thymus cancer	1.2e-05	0.000489	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAML2—thymus cancer	1.19e-05	0.000488	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAML2—thymus cancer	1.19e-05	0.000488	CbGpPWpGaD
Sorafenib—CDK7—Disease—KIT—thymus cancer	1.19e-05	0.000487	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—KIT—thymus cancer	1.19e-05	0.000485	CbGpPWpGaD
Sorafenib—RAF1—Insulin Signaling—AKT1—thymus cancer	1.18e-05	0.000484	CbGpPWpGaD
Sorafenib—RAF1—Downstream signal transduction—AKT1—thymus cancer	1.18e-05	0.000481	CbGpPWpGaD
Sorafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	1.17e-05	0.000479	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR—AKT1—thymus cancer	1.17e-05	0.000479	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB2—AKT1—thymus cancer	1.17e-05	0.000477	CbGpPWpGaD
Sorafenib—RAF1—DAP12 signaling—AKT1—thymus cancer	1.16e-05	0.000474	CbGpPWpGaD
Sorafenib—PDGFRB—Focal Adhesion—AKT1—thymus cancer	1.16e-05	0.000473	CbGpPWpGaD
Sorafenib—MAPK11—Metabolism of RNA—AKT1—thymus cancer	1.15e-05	0.00047	CbGpPWpGaD
Sorafenib—RAF1—MAPK Signaling Pathway—AKT1—thymus cancer	1.14e-05	0.000465	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD8A—thymus cancer	1.13e-05	0.000464	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD8A—thymus cancer	1.13e-05	0.000464	CbGpPWpGaD
Sorafenib—PDGFRB—B Cell Activation—AKT1—thymus cancer	1.13e-05	0.000463	CbGpPWpGaD
Sorafenib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	1.13e-05	0.000463	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAML2—thymus cancer	1.13e-05	0.000463	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAML2—thymus cancer	1.13e-05	0.000462	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—CD4—thymus cancer	1.12e-05	0.000457	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—CD4—thymus cancer	1.12e-05	0.000457	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—KIT—thymus cancer	1.11e-05	0.000454	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR in disease—AKT1—thymus cancer	1.09e-05	0.000446	CbGpPWpGaD
Sorafenib—RAF1—DAP12 interactions—AKT1—thymus cancer	1.09e-05	0.000446	CbGpPWpGaD
Sorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	1.09e-05	0.000446	CbGpPWpGaD
Sorafenib—ABCC4—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.09e-05	0.000444	CbGpPWpGaD
Sorafenib—MAPK11—Signaling by NGF—AKT1—thymus cancer	1.09e-05	0.000443	CbGpPWpGaD
Sorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	1.08e-05	0.000443	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR—AKT1—thymus cancer	1.08e-05	0.000442	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD8A—thymus cancer	1.08e-05	0.00044	CbGpPWpGaD
Sorafenib—BRAF—Signaling by NGF—AKT1—thymus cancer	1.08e-05	0.000439	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—CD4—thymus cancer	1.07e-05	0.000439	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—CD4—thymus cancer	1.07e-05	0.000439	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD8A—thymus cancer	1.07e-05	0.000439	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR in Cancer—AKT1—thymus cancer	1.07e-05	0.000438	CbGpPWpGaD
Sorafenib—RAF1—Signaling by PDGF—AKT1—thymus cancer	1.07e-05	0.000436	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KIT—thymus cancer	1.07e-05	0.000436	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KIT—thymus cancer	1.07e-05	0.000436	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CD4—thymus cancer	1.06e-05	0.000434	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CD4—thymus cancer	1.06e-05	0.000433	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle—TP53—thymus cancer	1.05e-05	0.000429	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—IL2—thymus cancer	1.03e-05	0.000422	CbGpPWpGaD
Sorafenib—RAF1—Focal Adhesion—AKT1—thymus cancer	1.03e-05	0.000422	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.03e-05	0.00042	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL2—thymus cancer	1.02e-05	0.000418	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—CD4—thymus cancer	1.02e-05	0.000417	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAML2—thymus cancer	1.02e-05	0.000416	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—CD4—thymus cancer	1.02e-05	0.000416	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL2—thymus cancer	1.01e-05	0.000411	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—AKT1—thymus cancer	9.79e-06	0.0004	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAML2—thymus cancer	9.7e-06	0.000397	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD8A—thymus cancer	9.67e-06	0.000395	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	9.67e-06	0.000395	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CD4—thymus cancer	9.54e-06	0.00039	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KIT—thymus cancer	9.45e-06	0.000386	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—AKT1—thymus cancer	9.29e-06	0.000379	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—AKT1—thymus cancer	9.26e-06	0.000379	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—CD4—thymus cancer	9.16e-06	0.000374	CbGpPWpGaD
Sorafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—thymus cancer	9.14e-06	0.000374	CbGpPWpGaD
Sorafenib—CDK7—Disease—CD4—thymus cancer	9.12e-06	0.000373	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAML2—thymus cancer	9.07e-06	0.000371	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling by Wnt—AKT1—thymus cancer	9.01e-06	0.000368	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—IL2—thymus cancer	8.69e-06	0.000355	CbGpPWpGaD
Sorafenib—BRAF—Disease—KIT—thymus cancer	8.64e-06	0.000353	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD8A—thymus cancer	8.62e-06	0.000352	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KIT—thymus cancer	8.52e-06	0.000348	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CD4—thymus cancer	8.5e-06	0.000347	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—AKT1—thymus cancer	8.35e-06	0.000341	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL2—thymus cancer	8.34e-06	0.000341	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—CD4—thymus cancer	8.17e-06	0.000334	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—AKT1—thymus cancer	8.15e-06	0.000333	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KIT—thymus cancer	8.08e-06	0.00033	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KIT—thymus cancer	8.06e-06	0.00033	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAML2—thymus cancer	7.83e-06	0.00032	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL2—thymus cancer	7.51e-06	0.000307	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KIT—thymus cancer	7.46e-06	0.000305	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KIT—thymus cancer	7.45e-06	0.000304	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—AKT1—thymus cancer	7.44e-06	0.000304	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KIT—thymus cancer	7.29e-06	0.000298	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KIT—thymus cancer	7.26e-06	0.000297	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CD4—thymus cancer	7.23e-06	0.000295	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KIT—thymus cancer	7.1e-06	0.00029	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—AKT1—thymus cancer	7.01e-06	0.000286	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KIT—thymus cancer	6.71e-06	0.000274	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL2—thymus cancer	6.65e-06	0.000272	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—AKT1—thymus cancer	6.64e-06	0.000271	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—thymus cancer	6.64e-06	0.000271	CbGpPWpGaD
Sorafenib—BRAF—Disease—CD4—thymus cancer	6.61e-06	0.00027	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—thymus cancer	6.57e-06	0.000269	CbGpPWpGaD
Sorafenib—KIT—Immune System—CD4—thymus cancer	6.52e-06	0.000266	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CD4—thymus cancer	6.52e-06	0.000266	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KIT—thymus cancer	6.48e-06	0.000265	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—thymus cancer	6.47e-06	0.000264	CbGpPWpGaD
Sorafenib—MKNK1—Disease—AKT1—thymus cancer	6.46e-06	0.000264	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—AKT1—thymus cancer	6.19e-06	0.000253	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CD4—thymus cancer	6.18e-06	0.000253	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CD4—thymus cancer	6.17e-06	0.000252	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KIT—thymus cancer	6.11e-06	0.00025	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KIT—thymus cancer	6.05e-06	0.000247	CbGpPWpGaD
Sorafenib—KIT—Disease—CD4—thymus cancer	6.02e-06	0.000246	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—AKT1—thymus cancer	6e-06	0.000245	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL2—thymus cancer	5.99e-06	0.000245	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL2—thymus cancer	5.99e-06	0.000245	CbGpPWpGaD
Sorafenib—RAF1—Disease—KIT—thymus cancer	5.98e-06	0.000244	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—IL2—thymus cancer	5.88e-06	0.00024	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	5.74e-06	0.000234	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CD4—thymus cancer	5.71e-06	0.000233	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CD4—thymus cancer	5.69e-06	0.000233	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL2—thymus cancer	5.69e-06	0.000232	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL2—thymus cancer	5.67e-06	0.000232	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—AKT1—thymus cancer	5.6e-06	0.000229	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—AKT1—thymus cancer	5.58e-06	0.000228	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—AKT1—thymus cancer	5.58e-06	0.000228	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—thymus cancer	5.58e-06	0.000228	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—thymus cancer	5.56e-06	0.000227	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—AKT1—thymus cancer	5.55e-06	0.000227	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KIT—thymus cancer	5.51e-06	0.000225	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—AKT1—thymus cancer	5.46e-06	0.000223	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—AKT1—thymus cancer	5.36e-06	0.000219	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—AKT1—thymus cancer	5.36e-06	0.000219	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—thymus cancer	5.36e-06	0.000219	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2—thymus cancer	5.34e-06	0.000218	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—AKT1—thymus cancer	5.3e-06	0.000216	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—AKT1—thymus cancer	5.28e-06	0.000216	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KIT—thymus cancer	5.23e-06	0.000214	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KIT—thymus cancer	5.21e-06	0.000213	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—thymus cancer	5.13e-06	0.00021	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—thymus cancer	5.13e-06	0.00021	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—thymus cancer	5.11e-06	0.000209	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—AKT1—thymus cancer	5.09e-06	0.000208	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—AKT1—thymus cancer	5.07e-06	0.000207	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—thymus cancer	5e-06	0.000204	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—thymus cancer	4.99e-06	0.000204	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—thymus cancer	4.95e-06	0.000202	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—AKT1—thymus cancer	4.9e-06	0.0002	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	4.84e-06	0.000198	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—thymus cancer	4.82e-06	0.000197	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—AKT1—thymus cancer	4.8e-06	0.000196	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—AKT1—thymus cancer	4.76e-06	0.000194	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—thymus cancer	4.74e-06	0.000194	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—AKT1—thymus cancer	4.71e-06	0.000193	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KIT—thymus cancer	4.7e-06	0.000192	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—thymus cancer	4.57e-06	0.000187	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—AKT1—thymus cancer	4.57e-06	0.000187	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—thymus cancer	4.56e-06	0.000186	CbGpPWpGaD
Sorafenib—CDK7—Disease—AKT1—thymus cancer	4.55e-06	0.000186	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—AKT1—thymus cancer	4.52e-06	0.000185	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KIT—thymus cancer	4.48e-06	0.000183	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—thymus cancer	4.31e-06	0.000176	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—thymus cancer	4.3e-06	0.000176	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—thymus cancer	4.26e-06	0.000174	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—AKT1—thymus cancer	4.24e-06	0.000173	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KIT—thymus cancer	4.19e-06	0.000171	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—AKT1—thymus cancer	4.07e-06	0.000166	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—AKT1—thymus cancer	4.07e-06	0.000166	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—thymus cancer	3.88e-06	0.000158	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—thymus cancer	3.88e-06	0.000158	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—thymus cancer	3.68e-06	0.00015	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—thymus cancer	3.67e-06	0.00015	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—thymus cancer	3.61e-06	0.000148	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—thymus cancer	3.61e-06	0.000147	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—thymus cancer	3.58e-06	0.000146	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—thymus cancer	3.31e-06	0.000135	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—thymus cancer	3.3e-06	0.000135	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—thymus cancer	3.29e-06	0.000135	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—thymus cancer	3.25e-06	0.000133	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—thymus cancer	3.25e-06	0.000133	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—thymus cancer	3.21e-06	0.000131	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—thymus cancer	3.19e-06	0.00013	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—thymus cancer	3.15e-06	0.000129	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—thymus cancer	3.09e-06	0.000126	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—thymus cancer	3.08e-06	0.000126	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—thymus cancer	3e-06	0.000123	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—thymus cancer	2.95e-06	0.00012	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—thymus cancer	2.89e-06	0.000118	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—thymus cancer	2.85e-06	0.000116	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—thymus cancer	2.84e-06	0.000116	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—thymus cancer	2.78e-06	0.000114	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—thymus cancer	2.77e-06	0.000113	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—thymus cancer	2.76e-06	0.000113	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—thymus cancer	2.73e-06	0.000112	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—thymus cancer	2.71e-06	0.000111	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—thymus cancer	2.7e-06	0.000111	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—thymus cancer	2.57e-06	0.000105	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—thymus cancer	2.56e-06	0.000105	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—thymus cancer	2.54e-06	0.000104	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—thymus cancer	2.49e-06	0.000102	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—thymus cancer	2.49e-06	0.000102	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—thymus cancer	2.47e-06	0.000101	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—thymus cancer	2.36e-06	9.65e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—thymus cancer	2.36e-06	9.63e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—thymus cancer	2.33e-06	9.54e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—thymus cancer	2.33e-06	9.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—thymus cancer	2.31e-06	9.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—thymus cancer	2.28e-06	9.32e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—thymus cancer	2.12e-06	8.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—thymus cancer	2.1e-06	8.59e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—thymus cancer	2.1e-06	8.59e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—thymus cancer	2.02e-06	8.27e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—thymus cancer	1.99e-06	8.15e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—thymus cancer	1.99e-06	8.13e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—thymus cancer	1.96e-06	8.03e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—thymus cancer	1.96e-06	8.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—thymus cancer	1.89e-06	7.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—thymus cancer	1.79e-06	7.32e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—thymus cancer	1.71e-06	6.98e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—thymus cancer	1.67e-06	6.81e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—thymus cancer	1.65e-06	6.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—thymus cancer	1.63e-06	6.67e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—thymus cancer	1.6e-06	6.53e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—thymus cancer	1.38e-06	5.64e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—thymus cancer	1.22e-06	4.99e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—thymus cancer	1.19e-06	4.88e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—thymus cancer	1.03e-06	4.23e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—thymus cancer	9.23e-07	3.77e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—thymus cancer	9.01e-07	3.68e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—thymus cancer	8.49e-07	3.47e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—thymus cancer	8.42e-07	3.44e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—thymus cancer	7.19e-07	2.94e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—thymus cancer	5.55e-07	2.27e-05	CbGpPWpGaD
